Cancer Management

Cancer Therapy Advisor’s cancer treatment resources now include the most recent guideline-based information to inform oncologists and oncology professionals about therapy selection for optimal patient outcomes. These articles provide accurate and up-to-date information about FDA-approved therapies commonly recommended in cancer treatment guidelines for different types of cancer, recent updates to US guidelines for cancer treatment, and adverse events and drug-drug interactions associated with certain therapies.

Sign up for the Cancer Therapy Advisor newsletter to stay up to date.

The CTA newsletter arrives in your inbox daily with the most current news and information on cancer research, new drugs for treatment, and helpful resources for clinicians.

ACCESS THE ARTICLE

Microscopic examination of the blood demonstrated acute myeloid leukemia.

Acute Myeloid Leukemia: Pharmacologic Management

Acute myeloid leukemia (AML) is the most prevalent adult acute leukemia. According to the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, as many as 20,380 cases of AML will be diagnosed in 2023.
ACCESS THE ARTICLE

Scaly erythematous patches on the chest and abdomen indicative of mycosis fungoides, the most common subtype of primary cutaneous T-cell lymphoma.

Adult T-Cell Lymphoma: Pharmacologic Management

Adult T-cell lymphoma is a rare type of non-Hodgkin lymphoma (NHL) that affects T lymphocytes and natural killer (NK) cells. They are a group of heterogeneous malignancies that account for 12% of all NHL cases
ACCESS THE ARTICLE

Anal Cancer: Pharmacologic Management

Anal cancer, of which fewer than 10,000 patients are diagnosed annually in the United States, is an uncommon type of cancer occurring in the tissue of the anus.
ACCESS THE ARTICLE

Photomicrograph reflecting intrahepatic cholangiocarcinoma

Biliary Tract Cancers: Pharmacologic Management

Biliary tract cancers are a rare but deadly form of cancer that account for 2% to 3% of all malignancies in the United States. Biliary tract cancer typically presents between the ages of 60 and 70 years.
ACCESS THE ARTICLE

Bladder Cancer Guidelines

The best bladder cancer treatment option may include more than one type or combination of different treatments (chemotherapy, radiation, and surgery).
ACCESS THE ARTICLE

G_bladder_cancer_micrograph

Bladder Cancer: Pharmacologic Management

Bladder cancer is the sixth most prevalent cancer in the United States. As of 2023, 82,290 new diagnoses of bladder cancer (62,420 in men and 19,870 in women) were documented, as well as 16,710 deaths.
ACCESS THE ARTICLE

Radiographic imaging demonstrating an ill-defined lytic lesion with wide zone transition and irregular periosteal reaction suggestive of an aggressive primary bone tumor (osteosarcoma).

Bone Cancer: Pharmacologic Management

Primary bone cancers are rare cancers that arise from primitive mesenchymal cells from which all connective tissues are derived. Bone cancer accounts for 0.2% of all cancers.
ACCESS THE ARTICLE

Colored computed tomographic (CT) imaging of the brain demonstrating glioblastoma, which is the most aggressive form of brain cancer.

Brain Cancer: Pharmacologic Management

Glioblastoma multiforme (GBM) is the most malignant and frequently diagnosed primary brain tumor, accounting for more than 60% of all brain cancer diagnoses in adults.
ACCESS THE ARTICLE

breast cancer cells

Breast Cancer: Pharmacologic Management

The National Cancer Institute estimates that there will be 297,790 new cases of invasive breast cancer and 55,720 new cases of ductal carcinoma in situ (DCIS) diagnosed in 2023.
ACCESS THE ARTICLE

Lymph node with metastatic colonic adenocarcinoma

Colon Cancer Guidelines

Colon cancer is the third most common cancer diagnosed in the United States. The overall lifetime risk of developing colorectal cancer is approximately 1 in 23 for men and 1 in 25 in women. Learn more about the staging, management, and prognosis of colon cancer.
ACCESS THE ARTICLE

Lymph node with metastatic colonic adenocarcinoma

Colorectal Cancer: Pharmacologic Management

Colorectal cancer is the third most common cancer and the second leading cause of cancer death in the United States.1 Colorectal cancer is an umbrella term that refers to cancer of both the colon and the rectum.
ACCESS THE ARTICLE

ACCESS THE ARTICLE

Magnetic resonance imaging demonstrating stage IIB cervical cancer that has spread to the parametria.

Cervical Cancer: Pharmacologic Management

Cervical cancer is the fourth most common cancer in women worldwide, with 604,000 new cases reported in 2020. In 2023, an estimated 13,960 new cases of cervical cancer will be diagnosed, and 4310 deaths will be attributed to the malignancy in the United States.
ACCESS THE ARTICLE

Figure. Microscopic image of a biopsy specimen from the superior iliac spine demonstrating chronic myeloid leukemia, with increased granulopoiesis, as well as hypercellular and crush artifacts noted.

Chronic Myeloid Leukemia: Pharmacologic Management

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a hematologic malignancy that arises from dysregulation of hematopoietic stem cells in the bone marrow (myeloproliferative neoplasm).
ACCESS THE ARTICLE

ACCESS THE ARTICLE

ACCESS THE ARTICLE

ACCESS THE ARTICLE

ACCESS THE ARTICLE

ACCESS THE ARTICLE

ACCESS THE ARTICLE

ACCESS THE ARTICLE

ACCESS THE ARTICLE

Epithelioid mesothelioma is a cancer subtype caused by asbestos. It is the most common mesothelioma cell type, accounting for 50% to 70% of cases.

Mesothelioma: Pharmacologic Management

Malignant mesothelioma is a rare cancer that arises from mesothelial cells; it occurs most commonly in the pleura and peritoneum but is also known to cause primary tumors in the testes and heart.
ACCESS THE ARTICLE

Chest radiograph of a woman with breast cancer demonstrating multiple nodules of variable sizes throughout the lungs, suggestive of pulmonary metastasis.

Metastatic Breast Cancer: Pharmacologic Management

Breast cancer is the most common type of cancer, with an estimated 300,590 new cases in the United States in 2023. The National Cancer Institute also estimates that breast cancer will account for 43,170 to 43,530 new deaths in 2023.
ACCESS THE ARTICLE

ACCESS THE ARTICLE

ACCESS THE ARTICLE

ACCESS THE ARTICLE

ACCESS THE ARTICLE

ACCESS THE ARTICLE

Pancreatic Cancer: Pharmacologic Management

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent pancreatic malignancy. This condition represents approximately 3% of all cancers in the United States and approximately 7% of all cancer deaths.
ACCESS THE ARTICLE

Figure. Photomicrograph of non-Hodgkin lymphoma, which includes peripheral T-cell lymphomas.

Peripheral T-Cell Lymphoma: Pharmacologic Management

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of cancers that affect mature T cells. They fall under the umbrella of non-Hodgkin lymphoma, which is anticipated to account for 4.1% of new cancer cases in 2023.
ACCESS THE ARTICLE

Pheochromocytoma (PH or PCC). Adrenal Gland Tumor

Pheochromocytoma Diagnosis & Treatment

Pheochromocytoma is a rare neuroendocrine disorder in which a tumor grows within the adrenal medulla. This tumor causes the continuous overproduction of epinephrine and norepinephrine, which, if left without treatment, can lead to severe or life-threatening damage to other body systems.
ACCESS THE ARTICLE

Pituitary Adenoma and Pregnancy

Pituitary adenomas are typically prolactinomas, which are the most frequent cause of elevated prolactin levels. Pituitary adenomas comprise over 85% of pituitary tumors, and 25% to 30% of these are hormonally inactive. The incidence of prolactinomas is four times greater in women than in men.
ACCESS THE ARTICLE

Urology consultation

Prostate Cancer Guidelines

Prostate cancer is the second most common type of cancer, and cancer death, in men in the United States with an estimated annual incidence of 268,490 cases and an estimated 34,500 deaths each year.
ACCESS THE ARTICLE

ACCESS THE ARTICLE

The new risk score, developed by Emory researchers, could be a useful tool for determining overall and progression-free survival after immunotherapy.

Renal Cell Carcinoma Guidelines

Renal Cell Carcinoma is the 10th most common cancer. Most renal cancers arise from the epithelial tubules of the nephron. This reference covers risk factors, testing, prognosis, and treatments.
ACCESS THE ARTICLE

ACCESS THE ARTICLE

ACCESS THE ARTICLE

ACCESS THE ARTICLE

ACCESS THE ARTICLE

Figure. Positron emission tomography (PT) and computed tomographic (CT) imaging of the thyroid gland.

Thyroid Cancer: Pharmacologic Management

Thyroid cancer — a malignancy affecting the thyroid gland, which is located in the front of the throat — occurs more frequently in women than men. Patients are often diagnosed with thyroid cancer at a younger age compared with most other cancers.
ACCESS THE ARTICLE

Axial T2-weighted magnetic resonance imaging (MRI) of the pelvis demonstrating uterine sarcoma.

Uterine Sarcoma: Pharmacologic Management

Uterine sarcoma is a rare type of uterine cancer that makes up less than 1% of all gynecologic malignancies and only 2% to 5% of uterine malignancies. In the United States, uterine carcinoma has an annual incidence of 0.36 to 0.64 cases per 100,000 women.
ACCESS THE ARTICLE

Photomicrograph demonstrating Waldenström macroglobulinemia, a rare type of cancer that begins in the white blood cells.

Waldenström Macroglobulinemia: Pharmacologic Management

Waldenström macroglobulinemia (WM) is a subtype of lymphoplasmacytic lymphoma (LPL), a rare type of non-Hodgkin lymphoma (NHL). WM results from the accumulation of immunoglobulin M (IgM) antibodies in the blood and lymphoplasmacytic cells in the bone marrow.
ACCESS THE ARTICLE